Reply.

We agree with Kulkarni et al on the potential role of splanchnic and peripheral vasoconstrictors in the treatment of HH. In our review (1), we summarize the sparse data on octreotide and terlipressin in HH management. However, there are currently no large studies or randomized trials on the use of these medications in HH, and evidence for their use is limited to case reports and case series. Most of the studies cited by Kulkarni et al examine these pharmacologic agents in the control of ascites, not HH per se.